New Biochip-based Blood Test Detects Elevated Risk for Alzheimer's Disease
Researchers at AACC Annual Scientific Meeting show test performs with same accuracy as gold standard DNA test
Researcher today unveiled results from a new blood test to help identify which patients are at an elevated risk of Alzheimer’s disease. The findings, presented at the 68th AACC Annual Scientific Meeting & Clinical Lab expo in Philadelphia, showed that the biochip test, which allows multiple tests to be run on one blood sample, was as accurate as existing molecular tests that analyze DNA. “This is the first time that we have used this biochip technology to test for an increased risk of Alzheimer’s disease,” said Emma C. Harte, PhD, a research scientist at Randox Laboratories. “This type of testing is important in our quest to undestand and diagnose Alzheimer’s and empower patients to understand risks, consider medication and even make early lifestyle changes.” To read more, click here.
2017 National Neuroscience Review
March 31-April 1, 2017; National Harbor, Md.
Brain & Brain PET 2017
April 1-4, 2017; Berlin, Germany
Neurosurgical Society of America Annual Meeting 2017
April 2-5, 2017; Jacksonville, Fla.
13th Head & Neck Cancer Symposium
April 6-7, 2017; Amsterdam, The Netherlands
Endoscopic and Endoscope-Assisted Neurosurgery Under FULL HD Visualization
April 6-7, 2017; Germany